Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BB 882; DO 6; GR 167089; Lexipafant - Vernalis; Zacutex

Latest Information Update: 09 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer DevCo Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antiplatelets; Branched-chain amino acids; Imidazoles; Neuroprotectants; Small molecules
  • Mechanism of Action Platelet activating factor inhibitors; Platelet activating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cognition disorders; Neurological disorders; Pancreatitis; Reperfusion injury
  • Discontinued Arrhythmias; Asthma; Ischaemic heart disorders; Multiple sclerosis

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 23 Mar 2004 Lexipafant is available for licensing (http://www.devcopharma.com)
  • 23 Mar 2004 Clinical data from a media release have been added to the pharmacokinetics section
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top